Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer

Hampson, Lindsay A.; Cowan, Janet E.; Zhao, Shoujun; Carroll, Peter R.; Cooperberg, Matthew R.

doi:10.1016/j.eururo.2015.01.008

Cited by 46 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the analyses by age, Hampson et al [45] and Penson et al [46] also found that younger men had worse mental health (as measured by the SF-36) compared to older men pre-treatment. Similarly, Eton, Lepore, and Helgeson observed better mental health among older men at approximately 7-weeks post treatment [47].…”

Section: Discussionmentioning

confidence: 99%

Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study

et al. 2016

View full text Add to dashboard Cite

Purpose: To evaluate the reliability and validity of six PROMIS measures (anxiety, depression, fatigue, pain interference, physical function, sleep disturbance) telephone-administered to a diverse, population-based cohort of localized prostate cancer patients. Methods: Newly-diagnosed men were enrolled in the North Carolina Prostate cancer Comparative Effectiveness and Survivorship Study. PROMIS measures were telephone-administered pre-treatment (baseline), and at 3-months and 12-months post-treatment initiation (N=778). Reliability was evaluated using Cronbach’s alpha. Dimensionality was examined with bifactor models and explained common variance (ECV). Ordinal logistic regression models were used to detect potential differential item functioning (DIF) for key demographic groups. Convergent and discriminant validity were assessed by correlations with the legacy instruments Memorial Anxiety Scale for Prostate Cancer and SF-12v2. Known-groups validity was examined by age, race/ethnicity, comorbidity, and treatment. Results: Each PROMIS measure had high Cronbach’s alpha values (0.86 to 0.96) and was sufficiently unidimensional. Floor effects were observed for anxiety, depression, and pain interference measures; ceiling effects were observed for physical function. No DIF was detected. Convergent validity was established with moderate to strong correlations between PROMIS and legacy measures (0.41 to 0.77) of similar constructs. Discriminant validity was demonstrated with weak correlations between measures of dissimilar domains (−0.20 to −0.31). PROMIS measures detected differences across age, race/ethnicity, and comorbidity groups; no differences were found by treatment. Conclusions: This study provides support for the reliability and construct validity of six PROMIS measures in prostate cancer, as well as the utility of telephone administration for assessing HRQoL in low literacy and hard-to-reach populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, men under 60 years’ experience greater reduction in quality of life after treatment compared to older men. 73 Still, in the absence of evidence, there remains concern that younger men with a long life expectancy may have more to lose by forgoing immediate cure. Reluctance to include younger men in AS programs stems from the limited data on outcomes beyond 20 years.…”

Section: As In Specific Patient Subgroupsmentioning

confidence: 99%

Active surveillance for prostate cancer: current evidence and contemporary state of practice

et al. 2016

View full text Add to dashboard Cite

Prostate cancer remains among the most commonly diagnosed malignancies worldwide. Early diagnosis and curative treatment appear to improve survival in men with unfavorable-risk cancers, but significant concerns exist regarding the overdiagnosis and overtreatment of men with lower-risk cancers. To this end, active surveillance (AS) has emerged as a primary management strategy in men with favorable-risk disease, and contemporary data suggest that use of AS has increased worldwide. Although published surveillance cohorts differ by protocol, reported rates of metastatic disease and prostate cancer-specific mortality are exceedingly low in the intermediate term (5–10 years). Such outcomes appear to be closely associated with program-specific criteria for selection, monitoring, and intervention, suggesting that AS – like other management strategies – could be individualized based on the level of risk acceptable to patients in light of personal preferences. Additional data are needed to better establish the risks associated with AS and to identify patient-specific characteristics that could modify prognosis.

show abstract

“…Hampson et al showed that older men have lower baseline sexual functioning scores, but also show less recovery after treatment [31]. In our study, 85% of our patients were over 60 years of age at the time of HDR-BT and 40% was even older than 70 years.…”

Section: Quality Of Life Assessmentmentioning

confidence: 53%

Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer

Aluwini

Busser

Alemayehu

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer

Cited by 46 publications

References 27 publications

Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study

Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study

Active surveillance for prostate cancer: current evidence and contemporary state of practice

Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer

Contact Info

Product

Resources

About